These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 23715572)

  • 1. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
    Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
    J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
    Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.
    Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Chianese-Bullock KA; Mauldin IS; Smith KT; Deacon DH; Varhegyi NE; Donnelly SB; Reed CM; Scott K; Galeassi NV; Grosh WW
    Cancer Immunol Immunother; 2016 Jan; 65(1):25-36. PubMed ID: 26581199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
    McQuade JL; Homsi J; Torres-Cabala CA; Bassett R; Popuri RM; James ML; Vence LM; Hwu WJ
    BMC Cancer; 2018 Dec; 18(1):1274. PubMed ID: 30567529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
    Szmania S; Gnjatic S; Tricot G; Stone K; Zhan F; Moreno A; Thuro B; Melenhorst J; Barrett J; Shaughnessy J; Old LJ; Barlogie B; Brichard VG; van Rhee F
    J Immunother; 2007; 30(8):847-54. PubMed ID: 18049337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
    Russo V; Pilla L; Lunghi F; Crocchiolo R; Greco R; Ciceri F; Maggioni D; Fontana R; Mukenge S; Rivoltini L; Rigamonti G; Mercuri SR; Nicoletti R; Maschio AD; Gianolli L; Fazio F; Marchianò A; Florio AD; Maio M; Salomoni M; Gallo-Stampino C; Fiacco MD; Lambiase A; Coulie PG; Patuzzo R; Parmiani G; Traversari C; Bordignon C; Santinami M; Bregni M
    Int J Cancer; 2013 Jun; 132(11):2557-66. PubMed ID: 23151995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys.
    Destexhe E; Grosdidier E; Baudson N; Forster R; Gerard C; Garçon N; Segal L
    J Appl Toxicol; 2015 Jul; 35(7):717-28. PubMed ID: 25219328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAGE-A3: an immunogenic target used in clinical practice.
    Esfandiary A; Ghafouri-Fard S
    Immunotherapy; 2015; 7(6):683-704. PubMed ID: 26100270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
    Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
    J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.
    Melssen MM; Pollack KE; Meneveau MO; Smolkin ME; Pinczewski J; Koeppel AF; Turner SD; Sol-Church K; Hickman A; Deacon DH; Petroni GR; Slingluff CL
    Cancer Immunol Immunother; 2021 Aug; 70(8):2151-2164. PubMed ID: 33454795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
    Saiag P; Gutzmer R; Ascierto PA; Maio M; Grob JJ; Murawa P; Dreno B; Ross M; Weber J; Hauschild A; Rutkowski P; Testori A; Levchenko E; Enk A; Misery L; Vanden Abeele C; Vojtek I; Peeters O; Brichard VG; Therasse P
    Ann Oncol; 2016 Oct; 27(10):1947-53. PubMed ID: 27502712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
    Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
    J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
    van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
    J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
    Pujol JL; Vansteenkiste JF; De Pas TM; Atanackovic D; Reck M; Thomeer M; Douillard JY; Fasola G; Potter V; Taylor P; Bosquée L; Scheubel R; Jarnjak S; Debois M; de Sousa Alves P; Louahed J; Brichard VG; Lehmann FF
    J Thorac Oncol; 2015 Oct; 10(10):1458-67. PubMed ID: 26309191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
    Kruit WH; van Ojik HH; Brichard VG; Escudier B; Dorval T; Dréno B; Patel P; van Baren N; Avril MF; Piperno S; Khammari A; Stas M; Ritter G; Lethé B; Godelaine D; Brasseur F; Zhang Y; van der Bruggen P; Boon T; Eggermont AM; Marchand M
    Int J Cancer; 2005 Nov; 117(4):596-604. PubMed ID: 15945101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.